Physician profile

Stacey B Knobler

Neurology with Special Qualifications in Child Neurology · Reno, NV

NPI 1073705273

$3,017.26

in general payments reported to CMS, 2019-2025

21 companies · none reported in 2025

See the full distribution for Neurology with Special Qualifications in Child Neurology

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $634.08 2019
Ucb, INC. $396.96 2019-2022
Eisai INC. $378.09 2019-2022
Takeda Pharmaceuticals U.S.A., INC. $328.74 2019-2021
Greenwich Biosciences, INC. $214.21 2019-2021
Supernus Pharmaceuticals, INC. $189.85 2019-2022
Tris Pharma INC $172.65 2019-2021
Sk Life Science, INC. $126.03 2020-2021
Zogenix INC. $110.59 2021
Neurelis, INC. $109.00 2020-2022
Aquestive Therapeutics, INC. $67.57 2020-2021
Ptc Therapeutics, INC. $56.10 2021
Jazz Pharmaceuticals INC. $40.49 2022
Upsher-Smith Laboratories LLC $37.99 2019
Biocodex, INC. $37.20 2021-2022
Show all 21 companies
CompanyGeneral paymentsYearsTop products
Harmony Biosciences LLC $24.24 2022
Genzyme Corporation $22.81 2019
Novartis Pharmaceuticals Corporation $20.87 2019
Biomarin Pharmaceutical INC. $17.30 2019
Astrazeneca Pharmaceuticals LP $16.63 2021
Alexion Pharmaceuticals, INC. $15.86 2022

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Stacey B Knobler

$3,017.26

in general payments reported 2019-2025

Years
2019-2022
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/276079/stacey-b-knobler

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.